, AstraZeneca to Begin Supplying COVID-19 Vaccine in September
The University of Oxford and AstraZeneca Plc have begun recruiting over 10,000 subjects for advanced human trials of experimental COVID-19 vaccine. If everything goes …
, Remdesivir Shortens Recovery Period of Covid-19 Patients, Still Under Experiment
Remdesivir, an experimental drug, is being tested on patients to determine its efficacy against the COVID-19 in people suffering from mild to severe respiratory …
, ATMOBLUE: Smart Mask That Delivers 99.5% Filtered Air
Face masks have become the most ubiquitous item of functionality in today’s world. Earlier, only health care workers and hygiene conscious and pollution weary …
, Surge In Demand for Marijuana during Lockdown Favors Pot Stocks
Pot stocks are seeing unprecedented gains after suffering some initial lows in the coronavirus crisis. As the coronavirus spread, the United States government and …
, Gene-editing feature CRISPR could restore sight to blind people
CRISPR inspires new hope to the visually impaired.
, Shortfall in diagnostic kits for coronavirus shows preparation gap in US healthcare facilities
Coronavirus has been declared a pandemic by the World Health Organization. This global crisis has plunged the world into a state of panic with …
, Pharma Industry faces clinical trial woes due to Coronavirus in China
The Covid 19 Coronavirus far from being contained is finding new victims every day. With almost all parts of the world reporting cases, concerns …
, Thermo Fisher pays $11.5 billion for Qiagen NV
Thermo Fisher Scientific Inc., the laboratory equipment manufacturer, plans to acquire Qiagen NV, a Dutch diagnostics and molecular testing company for $11.5 billion. The deal …
, World Bank Pandemic Bonds face losses following Coronavirus spread
Investors holding the World Bank’s Pandemic bonds may be facing losses as the coronavirus outbreak spreads to more countries and the death rate escalates. The …
, PPD Raises $1.6 Billion in IPO
PPD Inc, the drug research and biotech company, raised more than $1.6 billion in its initial public offering. Its 60 million shares were sold …
, Researchers Reverse HIV Dormancy, Paving Way for Better Treatment of Disease
A full cure for Human immunodeficiency Virus (HIV) has been hindered by the inability of scientists to contain latency of the disease in hidden …
, What Novartis’ Potential Acquisition of The Medicines Company Means for the Industry Leader
In the recent deal, Novartis on 24th November 2019 announced that it was going to buy The Medicines Company for $9.7 billion. The pharmaceutical …
, Purdue Pharma Bankruptcy angers claimants
Purdue Pharma, the drug company that made billions selling the controversial pain medication OxyContin, filed for bankruptcy in White Plains, New York on late …
, Animal healthcare is in an economic boom
A gamut of new products is available to treat hair loss, itchy skin, influenza, nutritional deficiencies, and weight loss. You’re mistaken if you believe …
, Who are the industry leaders in animal health?
In the September issue of Industry Leaders, we pondered on the longevity of the economic boom in the global animal health market. According to …
, E-cigarette giant Juul Labs accused of peddling death to teens
E-cigarette giant Juul Labs is facing investigation by the Federal Trade Commission (FTC) in regards to how the company’s vaping device became so popular …
, Bayer deal could leapfrog Elanco to become industry leader
Elanco Animal Health said on Tuesday it would buy Bayer’s veterinary drugs unit in a deal worth $7.6 billion, creating the second-largest animal health …
, ‘Magic Mushrooms’ are better than Antidepressants, study finds
50-year old part-time web developer Michael had battled with depression for the most part of his life. Different types of antidepressant and talking therapies …
, Hemp Farming Nears Legal Status after Almost a Century
Congress has adopted a proposed legislation that could officially legalize hemp production in the United States. The legalization bill, which is coming after nearly …
, Brexit shows no signs of mercy to drugmakers
Britain’s departure from the EU has forced companies including AstraZeneca Plc, GlaxoSmithKline Plc and Merck & Co. to build stockpiles of their medicines in …
, Starbucks Corp banks on a new partner to remain afloat in New Zealand
Starbucks New Zealand franchise holder, Fast-food group Restaurant Brands, is giving up the license for $2.9 million (NZ$4.4 million) as it looks forward to …
